Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALNA Allena Pharmaceuticals		$0.07	$0.06 ▼ $1.17	$37K	1.13	15.69 million shs	96,558 shs
CRIS Curis	$1.84 +5.1%	$2.19	$1.02 ▼ $8.29	$18.94M	3.6	79,828 shs	131,473 shs
IDRA Idera Pharmaceuticals		$0.50	$0.22 ▼ $8.67	$450.52M	1.25	464,030 shs	21,870 shs
INMB INmune Bio	$2.61 +10.4%	$6.88	$1.89 ▼ $11.64	$59.67M	1.34	778,332 shs	4.70 million shs
VXRT Vaxart	$0.43 -1.4%	$0.47	$0.29 ▼ $1.07	$97.49M	1.14	2.46 million shs	1.62 million shs

20 High-Yield Dividend Stocks that Could Ruin Your Retirement

Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALNA Allena Pharmaceuticals	0.00%	0.00%	0.00%	0.00%	0.00%
CRIS Curis	0.00%	-15.21%	-22.03%	+49.59%	-70.56%
IDRA Idera Pharmaceuticals	0.00%	0.00%	0.00%	0.00%	0.00%
INMB INmune Bio	0.00%	-51.13%	-65.86%	-64.17%	-67.40%
VXRT Vaxart	0.00%	-12.64%	+6.93%	+28.38%	-33.05%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ALNA Allena Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
CRIS Curis	2.8912 of 5 stars	3.5	5.0	0.0	0.0	2.3	0.0	0.6
IDRA Idera Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
INMB INmune Bio	1.6211 of 5 stars	3.3	0.0	0.0	0.0	2.0	1.7	0.6
VXRT Vaxart	2.2865 of 5 stars	3.5	1.0	0.0	0.0	2.6	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALNA Allena Pharmaceuticals	0.00	N/A	N/A	N/A
CRIS Curis	3.00	Buy	$17.00	823.91% Upside
IDRA Idera Pharmaceuticals	0.00	N/A	N/A	N/A
INMB INmune Bio	2.57	Moderate Buy	$18.40	606.33% Upside
VXRT Vaxart	3.00	Buy	$3.00	594.44% Upside

Current Analyst Ratings Breakdown

Latest VXRT, IDRA, ALNA, CRIS, and INMB Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/2/2025	INMB INmune Bio	Maxim Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$30.00 ➝ $8.00
7/1/2025	INMB INmune Bio	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Neutral
7/1/2025	INMB INmune Bio	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sector Outperform ➝ Sector Underperform
6/30/2025	INMB INmune Bio	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Moderate Buy ➝ Hold
5/19/2025	CRIS Curis	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy	$17.00

(Data available from 7/5/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALNA Allena Pharmaceuticals	N/A	N/A	N/A	N/A	$0.23 per share	N/A
CRIS Curis	$10.91M	1.76	N/A	N/A	($0.71) per share	-2.59
IDRA Idera Pharmaceuticals	N/A	N/A	N/A	0.29	$0.56 per share	N/A
INMB INmune Bio	$10K	6,142.59	N/A	N/A	$1.45 per share	1.80
VXRT Vaxart	$28.70M	3.44	N/A	N/A	$0.26 per share	1.66

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALNA Allena Pharmaceuticals	-$48.66M	N/A	0.00	N/A	N/A	N/A	-287.46%	-146.58%	N/A
CRIS Curis	-$43.39M	-$6.23	N/A	N/A	N/A	-376.08%	N/A	-97.14%	7/30/2025 (Estimated)
IDRA Idera Pharmaceuticals	$98.09M	-$0.32	N/A	N/A	N/A	N/A	-68.74%	-34.26%	N/A
INMB INmune Bio	-$42.08M	-$1.93	N/A	N/A	N/A	N/A	-119.35%	-89.37%	7/30/2025 (Estimated)
VXRT Vaxart	-$66.95M	-$0.27	N/A	N/A	N/A	-122.63%	-91.89%	-38.40%	8/14/2025 (Estimated)

Latest VXRT, IDRA, ALNA, CRIS, and INMB Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/13/2025	Q1 2025	VXRT Vaxart	-$0.07	-$0.07	N/A	-$0.07	$2.85 million	$20.88 million
5/8/2025	Q1 2025	INMB INmune Bio	-$0.43	-$0.43	N/A	-$0.43	N/A	$0.05 million
5/6/2025	Q1 2025	CRIS Curis	-$1.14	-$1.25	-$0.11	-$1.25	$2.37 million	$2.38 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALNA Allena Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
CRIS Curis	N/A	N/A	N/A	N/A	N/A
IDRA Idera Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
INMB INmune Bio	N/A	N/A	N/A	N/A	N/A
VXRT Vaxart	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALNA Allena Pharmaceuticals	N/A	1.58	1.58
CRIS Curis	N/A	1.23	1.23
IDRA Idera Pharmaceuticals	N/A	1.56	1.56
INMB INmune Bio	N/A	2.64	2.64
VXRT Vaxart	N/A	0.64	0.64

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALNA Allena Pharmaceuticals	7.33%
CRIS Curis	29.97%
IDRA Idera Pharmaceuticals	12.18%
INMB INmune Bio	12.72%
VXRT Vaxart	18.05%

Insider Ownership

Company	Insider Ownership
ALNA Allena Pharmaceuticals	3.70%
CRIS Curis	5.45%
IDRA Idera Pharmaceuticals	5.05%
INMB INmune Bio	35.70%
VXRT Vaxart	2.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALNA Allena Pharmaceuticals	35	122.08 million	117.57 million	Not Optionable
CRIS Curis	60	10.46 million	9.89 million	No Data
IDRA Idera Pharmaceuticals	32	62.36 million	59.21 million	Optionable
INMB INmune Bio	10	23.58 million	15.17 million	Optionable
VXRT Vaxart	120	228.31 million	221.69 million	Optionable

VXRT, IDRA, ALNA, CRIS, and INMB Headlines

Recent News About These Companies

Vaxart (NASDAQ:VXRT) Share Price Crosses Below Two Hundred Day Moving Average - Here's Why

July 3 at 4:57 AM | marketbeat.com

Vaxart (NASDAQ:VXRT) Share Price Crosses Below 200-Day Moving Average - Here's What Happened

June 25, 2025 | marketbeat.com

Vaxart (NASDAQ:VXRT) Shares Cross Below 200 Day Moving Average - Should You Sell?

June 14, 2025 | marketbeat.com

Vaxart Announces Preliminary Results of Annual Meeting of Stockholders

June 13, 2025 | globenewswire.com

Vaxart Reports Positive Clinical Data Demonstrating that its Second-Generation Vaccine Technology Produces Much Stronger Antibody Responses than its First-Generation Technology

June 11, 2025 | globenewswire.com

Vaxart, Inc. to Release Topline Data from Norovirus Phase I Trial on June 11, 2025

June 10, 2025 | quiverquant.comQ

Vaxart to Host Conference Call on June 11 at 8:30 AM ET to Discuss Topline Results from Its Phase I Norovirus Trial

June 10, 2025 | globenewswire.com

Vaxart Announces Adjournment of Annual Meeting of Stockholders

June 2, 2025 | globenewswire.com

Vaxart to Participate at the Jefferies Global Healthcare Conference on June 5, 2025

May 29, 2025 | globenewswire.com

Vaxart's Dr. Sean Tucker Calls on Stockholders to Support Reverse Stock Split Proposal by June 1, 2025

May 29, 2025 | quiverquant.comQ

Vaxart's Founder and Chief Scientific Officer Provides Video Update to Stockholders

May 29, 2025 | globenewswire.com

Vaxart Discusses Reverse Stock Split and Capital Raise

May 28, 2025 | tipranks.com

Vaxart Answers Additional Frequently Asked Questions from Retail Investors

May 28, 2025 | globenewswire.com

Vaxart Initiates Dosing in 10,000-Participant Portion of Phase 2b COVID-19 Trial

May 27, 2025 | globenewswire.com

Vaxart Announces Adjournment of Annual Meeting of Stockholders

May 21, 2025 | globenewswire.com

Vaxart, Inc. Grants Equity Awards to New CFO Jeroen Grasman

May 20, 2025 | quiverquant.comQ

Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | VXRT Stock News

May 20, 2025 | gurufocus.com

Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

May 20, 2025 | globenewswire.com

Vaxart, Inc. (NASDAQ:VXRT) Insider Steven Lo Acquires 100,000 Shares

May 20, 2025 | insidertrades.com

Vaxart Approves Resolutions to Narrow Proposed Reverse Split Range and Proposes Reducing Authorized Shares at Future Stockholder Meeting

May 16, 2025 | globenewswire.com

Vaxart Receives BARDA Approval to Initiate Dosing in 10,000-Participant Portion of Phase 2b COVID-19 Trial

May 15, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Why BigBear.ai Could Rally 100% and Catch Palantir Soon
By Gabriel Osorio-Mazilli | June 30, 2025
View Why BigBear.ai Could Rally 100% and Catch Palantir Soon
IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
By Dan Schmidt | June 20, 2025
View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
BigBear.ai Poised to Benefit as Palantir Dominates AI Defense
By Gabriel Osorio-Mazilli | June 23, 2025
View BigBear.ai Poised to Benefit as Palantir Dominates AI Defense
Intel's Turnaround Strategy Shifts From Planning to Attack Mode
By Jeffrey Neal Johnson | June 20, 2025
View Intel's Turnaround Strategy Shifts From Planning to Attack Mode
The Ultimate Trump Bump: These Gov't Backed Stocks Are Exploding
By Leo Miller | July 2, 2025
View The Ultimate Trump Bump: These Gov't Backed Stocks Are Exploding

VXRT, IDRA, ALNA, CRIS, and INMB Company Descriptions

Allena Pharmaceuticals NASDAQ:ALNA

Allena Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States. Its lead product candidate is ALLN-346, a novel and urate degrading enzyme for patients with hyperuricemia and gout in the setting of advanced chronic kidney disease. The company was incorporated in 2011 and is headquartered in Newton, Massachusetts.

Curis NASDAQ:CRIS

$1.84 +0.09 (+5.14%)

Closing price 07/3/2025 01:59 PM Eastern

Extended Trading

$1.78 -0.06 (-2.99%)

As of 07/3/2025 04:05 PM Eastern

Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single arm expansion trial in patients with relapsed or refractory, or R/R, AML and high-risk myelodysplastic syndromes. The company's pipeline also includes Fimepinostat, an oral dual inhibitor of HDAC and PI3K enzymes for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma; CA-170, an oral, small molecule antagonist designated as CA-170 that selectively targets PD-L1 and VISTA; and CA-327, an oral, small molecule, TIM3/PD-L1, which is a molecule antagonist of PD-L1 and TIM3. It has collaboration agreement with Genentech Inc., or Genentech and F. Hoffmann-La Roche Ltd, or Roche, for the commercialization of Erivedge, an orally-administered small molecule hedgehog signaling pathway antagonist for the treatment of advanced basal cell carcinoma, or BCC; Aurigene Discovery Technologies Limited for the discovery, development, and commercialization of small molecule compounds in the areas of immuno-oncology and precision oncology; and also licensed four programs under the Aurigene collaboration, including emavusertib. Curis, Inc. was incorporated in 2000 and is headquartered in Lexington, Massachusetts.

Idera Pharmaceuticals NASDAQ:IDRA

Aceragen, Inc. is a clinical stage biopharmaceutical company, which focuses on the clinical development, and commercialization of drug candidates for both oncology and rare disease indications. The company was founded by Paul C. Zamecnik, Sudhir A. Agrawal, and James B. Wyngaarden on May 25, 1989 and is headquartered in Exton, PA.

INmune Bio NASDAQ:INMB

$2.60 +0.25 (+10.38%)

Closing price 07/3/2025 03:57 PM Eastern

Extended Trading

$2.55 -0.06 (-2.11%)

As of 07/3/2025 04:58 PM Eastern

INmune Bio, Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. The company's development programs include INKmune, which is in Phase 1 for the treatment of patients with high-risk myelodysplastic syndrome; and INB03, a mucinous polyglucan on the surface of some epithelial cancer cells that appears to predict resistant to immunotherapy, including women with MUC4 expressing HER2+ breast cancer and other MUC4 resistant cancers. It also provides XPro1595 for the treatment of Alzheimer's disease and treatment resistant depression. It has license agreements with Xencor, Inc.; Immune Ventures, LLC; and University of Pittsburg. INmune Bio, Inc. was incorporated in 2015 and is headquartered in Boca Raton, Florida.

Vaxart NASDAQ:VXRT

$0.43 -0.01 (-1.37%)

Closing price 07/3/2025 03:58 PM Eastern

Extended Trading

$0.43 0.00 (-0.46%)

As of 07/3/2025 04:57 PM Eastern

Vaxart, Inc., a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions. It has a license agreement with Altesa Biosciences, Inc. to develop and commercialize Vapendavir, a capsid-binding broad-spectrum antiviral. Vaxart, Inc. is headquartered in South San Francisco, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time